Second-and third-generation ALK inhibitors for non-small cell lung cancer
J Wu, J Savooji, D Liu - Journal of hematology & oncology, 2016 - Springer
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated
non-small cell lung cancer (NSCLC). Second-and third-generation ALK inhibitors are …
non-small cell lung cancer (NSCLC). Second-and third-generation ALK inhibitors are …
Renal injury during long-term crizotinib therapy
T Yasuma, T Kobayashi… - International Journal of …, 2018 - mdpi.com
Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros
oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with …
oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with …
Renal complication of crizotinib: Crizotinib-associated complex renal cyst
W Jutidamrongphan… - The ASEAN Journal …, 2020 - asean-journal-radiology.org
Crizotinib is one of the first generations of tyrosine kinase inhibitors targeting anaplastic
lymphoma kinase (ALK) and is recently found to be associated with the development of …
lymphoma kinase (ALK) and is recently found to be associated with the development of …
Variables affecting evaluation and publication of oncology case reports: a systematic analysis
Background Studies on factors affecting editorial decisions of scientific journals are scarce.
In this study, we focused on case reports submitted to oncology journals and analyzed …
In this study, we focused on case reports submitted to oncology journals and analyzed …